Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement

JAMA. 2017 Jun 27;317(24):2479-2480. doi: 10.1001/jama.2017.5784.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Advertising / legislation & jurisprudence
  • Advertising / methods
  • Awareness*
  • Direct-to-Consumer Advertising / legislation & jurisprudence
  • Direct-to-Consumer Advertising / methods*
  • Drug Industry* / legislation & jurisprudence
  • Drug Industry* / standards
  • Drug Prescriptions
  • Humans
  • Janus Kinase 2 / genetics
  • Marketing / methods
  • Marketing / standards
  • Medical Overuse
  • Medicine in the Arts*
  • Myeloproliferative Disorders / therapy
  • Patient Acceptance of Health Care
  • Polycythemia Vera / diagnosis
  • Polycythemia Vera / therapy
  • Pyrazoles / therapeutic use
  • Rare Diseases* / diagnosis
  • Rare Diseases* / psychology
  • Rare Diseases* / therapy
  • Television*
  • United States

Substances

  • INCB018424
  • Pyrazoles
  • JAK2 protein, human
  • Janus Kinase 2